Patient description: The patient is a 14-year-old boy complaining of scoliosis and back pain. He has no other medical condition. He used to be able to play routine activities such as basketball and soccer, however, he recently has problem doing them. The pain is in his leg and back and aggravated by physical activities. He prefer lying down most of the time. He is not happy with his body gesture and complaints of shoulder imbalance and shifting his head to right. Patient is a well-dressed and well-nourished adolescent who is alert and cooperative. The left shoulder is slightly higher than the right shoulder. The scoliotic curve is measured as 45 degree. The patients is candidate for scoliosis surgery according to perioperative MEP monitoring

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Diffuse Astrocytoma, IDH-Wildtype Recurrent Glioblastoma Histopathologically proven diagnosis of glioblastoma, OR molecular diagnosis of glioblastoma per Consortium to Inform Molecular and Practical Approaches to Central Nervous System Tumor Taxonomy (c-IMPACT-NOW) ("diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, World Health Organization [WHO] grade IV"; this requires presence of amplification of EGFR, whole chromosome 7 gain AND whole chromosome 10 loss, or TERT promoter mutation) Tumor that is in first recurrence following prior first-line radiation therapy (prior dose >= 40 Gy). Prior temozolomide, prior tumor-treating fields, and/or Gliadel wafers (if placed at initial tumor resection) are allowed, but none of these are required Unequivocal radiographic evidence of tumor progression by contrast-enhanced magnetic resonance imaging (MRI) scan within 21 days prior to registration Per radiation oncologist review of MRI within 21 days prior to registration, must have focus of progressive, contrast-enhancing tumor that is amenable to FSRT, defined as the following At least 1 cm x 1 cm contrast-enhancing tumor that is no greater than 4 cm in largest dimension FSRT target is at least 0.5 cm from the optic chiasm and brainstem Of note, multifocal disease (i.e., other sites of tumor beyond the tumor being targeted for FSRT) is allowed if the above are met for the tumor that is the proposed target for FSRT Surgical cohort only (Phase II only) Must be a candidate for repeat surgery (significant debulking or gross total resection of the contrast enhancing area) as determined by the neurosurgeon or multidisciplinary team Must have confirmation of tumor progression via a biopsy  Known somatic tumor mutation in IDH1 or IDH2 gene. If not previously completed, sequencing of the IDH1 and IDH2 genes is not required to determine trial Known germline DNA repair defect (mismatch repair deficiency, POLE mutation, e.g.). If not previously completed, germline sequencing is not required to determine trial Diffuse leptomeningeal disease Known contrast-enhancing tumor in brainstem or spinal cord. If not previously completed, spinal imaging is not required to determine trial Patients with clinically significant mass effect or midline shift (e.g., 1-2 cm of midline shift) Prior bevacizumab therapy Patients with a prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of the investigational regimen are excluded from this trial. Otherwise, patients with prior or concurrent malignancy are eligible Patients with prior allogeneic bone marrow transplantation or prior solid organ transplantation Prior treatment with anti-PD-1, anti-PD-L1, or anti-CTLA-4 therapeutic antibody or pathway-targeting agents Treatment with systemic immunostimulatory agents (including, but not limited to, interferon [IFN]-alpha or interleukin [IL]-2) within 4 weeks prior to registration